Accueil   Diary - News   All news 11 MedTech SMEs supported by the Auvergne-Rhône-Alpes Region in their compliance with the new European regulation

11 MedTech SMEs supported by the Auvergne-Rhône-Alpes Region in their compliance with the new European regulation

 

The Auvergne-Rhône-Alpes Region  released a new budget of €200,000through its support scheme for SMEs in the medical devices sector. This initiative should enable these structures to deal with the regulatory changes in the EU 2017/745 medical CE marking as smoothly as possible. This support is set up in the form of a partnership  between the Auvergne-Rhône-Alpes Regional Economic Agency, the companies, Lyonbiopole health competitiveness cluster, and the Syndicat national de l'industrie des technologies industry (Snitem). 

 

Individual support for the 11 laureate companies

 

The current health crisis prompted the Auvergne-Rhône-Alpes Region to launch a 3rd Call for Expressions of Interest last October, just after the results of the second call for MedTech SMEs were announced, which represent a major boost for the region.

 

Of the 18 applications submitted, 11 were selected to receive financial aid and individual coaching. Although only three of these SMEs are members of Lyonbiopole, the competitiveness cluster plays a full role in the emergence and roll-out of support systems for companies in the Auvergne-Rhône-Alpes health sector, even beyond the restricted circle of its members.

 

The 11 winning companies will receive individual support which will cover up to 50% of their expenses, up to a maximum of €20,000 in services. Beforehand, Snitem will also offer individual meetings to each winner to carry out a regulatory diagnosis.

 

Focus on the winners

 

ALLYON develops and distributes surgical instruments, in particular those dedicated to spinal surgery, including retractors. These instruments are innovative because they respond to the multiple constraints of surgical centres: through the operating techniques they allow, the simplicity of use and management they provide, as well as the economic model which increases their availability and thus facilitates the programming and the number of patients who can be treated.

 

BIOSPEEDIA, a spin-off of the Institut Pasteur, designs, develops, produces and markets rapid diagnostic tests (RDTs) mainly oriented towards serious infectious diseases and/or those with a high epidemic potential.

 

Electroducer develops an innovative class IIa medical device, the Electroducer Sleeve, which simplifies percutaneous cardiac valvular and coronary interventions, while improving patient safety and comfort.


EMC Evolution specialises in the design, manufacture and distribution of vaginal and anal perineo-sphincter rehabilitation probes, in cases of lower urinary tract disorders or disorders of the anorectal function.

 

GEMOPTICS manufactures protective eyewear in France, particularly against viruses or in contaminated environments.

 

Kappa City Biotech develops in vitro diagnostic medical devices and more specifically lateral flow immunochromatographic tests, i.e. rapid tests that operate on the principle of tests based on the principle of an antibody/antigen reaction.

 

Kurage develops “neuroprosthesis” type medical devices using neuromuscular functional stimulation technology to replace the motor control of the central nervous system. These devices enable paralysed or weak limbs of neuro-linked people to be remobilised for functional movements such as lifting the feet, cycling, rowing and, potentially, walking.

 

Life Medical Control specialises in medical engineering. It is developing NeuroCoach, a solution for the prevention of risk factors for stroke.

 

NOXELIS aims to research, develop and manufacture a portfolio of medical products whose objective is to provide innovative treatments with excellent safety and high performance for patients suffering from ocular surface pathologies.

 

Stabyl designs, develops and markets medical devices for dental biotechnology, such as precision drill and root pin systems and syringes with built-in filling systems for the injection of impression materials.


SurgAR is developing and aims to market a suite of augmented reality (AR) software for minimally invasive surgery (laparoscopy), performed through a camera and small incisions. Its software provides surgeons with transparency of organs (uterus, liver and kidney) by merging in real time the preoperative imaging with the surgical view.

 

These 11 companies were selected on the basis of various criteria, namely the clarity of the need and objectives, consistency with the company's strategy, the prospects for economic benefits for the company and the region, and the relevance and leverage effect of the aid in relation to the project. A summary report will have to be provided by all these companies, describing the missions carried out.